Zoetis is a global leader in animal health, dedicated to providing innovative products and solutions that enhance the health and well-being of animals. The company develops a broad range of medicines, vaccines, and diagnostic tools for both livestock and companion animals, supporting veterinarians and producers in improving animal health through science-based products. With a commitment to advancing veterinary medicine and sustainability, Zoetis works to ensure safe and sustainable food supply chains while enhancing the quality of life for pets and livestock around the world. Read More
LANSING, MI – Shares of Neogen Corporation (NASDAQ: NEOG) experienced a dramatic surge in early trading today, climbing nearly 29% after the food and animal safety leader reported second-quarter fiscal 2026 financial results that blew past Wall Street expectations. The performance marks a definitive "return to growth" for the company, which
As 2025 comes to a close, the financial landscape of the pet care industry has been fundamentally reshaped by a tidal wave of mergers and acquisitions. What began as a post-pandemic stabilization period in early 2024 transformed into a historic consolidation frenzy, with the sector recording a staggering 532 transactions
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, February 12, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2025 financial results and respond to questions from financial analysts.
As the curtain closes on 2025, the healthcare sector has emerged as a landscape of stark contrasts. While traditional pharmaceutical giants have grappled with the implementation of the Medicare Part D out-of-pocket caps and shifting regulatory winds, two specific "growth pockets"—animal health and specialty/complex generics—have captured investor
In a significant strategic shift that marks the end of a multi-year regulatory odyssey, ImmuCell Corporation (Nasdaq: ICCC) announced late yesterday, December 23, 2025, that it has received another Technical Section Incomplete Letter from the U.S. Food and Drug Administration (FDA) regarding its subclinical mastitis treatment, Re-Tain. The letter,
Zoetis Inc. (NYSE:ZTS) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 10:30 a.m. PT.
Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
Zoetis Inc. (NYSE: ZTS) (the “Company” or “Zoetis”) today announced that it has priced its previously announced offering of $1.75 billion aggregate principal amount of 0.25% convertible senior notes due 2029 (the “Notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securities Act of 1933, as amended (the “Securities Act”). Zoetis has also granted the initial purchasers of the Notes an option to purchase, for settlement within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $250 million aggregate principal amount of Notes. The offering is expected to close on December 18, 2025, subject to the satisfaction of customary closing conditions.
Zoetis Inc. (NYSE: ZTS) (the “Company” or “Zoetis”) today announced that, subject to market conditions, it intends to offer $1.75 billion aggregate principal amount of convertible senior notes due 2029 (the “Notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securities Act of 1933, as amended (the “Securities Act”). Zoetis also intends to grant the initial purchasers of the Notes an option to purchase, for settlement within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $250 million aggregate principal amount of Notes.
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the first quarter of 2026, an increase of 6% from the quarterly dividend rate paid in 2025. The dividend will be paid on Tuesday, March 3, 2026, to all holders of record of the Company’s common stock as of the close of business on Tuesday, January 20, 2026.
Free cash flow is one of the most reliable indicators of financial durability.
These businesses not only generate cash but reinvest intelligently to sustain momentum.
Zoetis Inc. today announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three months of OA pain relief with a single injection, Portela targets anti-nerve growth factor (NGF), which is a key mediator of OA pain and inflammation.
Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Tuesday. Discover the gap up and gap down stocks in the S&P500 index.
Zoetis Inc. (NYSE: ZTS), the world’s leading animal health company, will host an Innovation Webcast today at 8:30 a.m. ET to provide an update on its proven innovation model, robust and diversified R&D pipeline, and upcoming growth catalysts as the company continues pioneering the future of animal health.
Rock-bottom prices don't always mean rock-bottom businesses.
The stocks we're examining today have all touched their 52-week lows, creating a classic investor's dilemma: bargain opportunity or value trap?
Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia® (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs.
